Roche, a Swiss multinational healthcare company, agreed to acquire the point of care technology platform of LumiraDx, a next generation point of care diagnostics company, for $350m. “Since our founding, we have sought to transform community-based healthcare by consolidating multiple Point of Care tests on a single instrument. We are excited to enter into this agreement with Roche as it will enable us to continue our important work and increase the reach of our innovative technology around the globe. This will enable more patients to get fast and easy access to better diagnostic testing,” Veronique Ameye, LumiraDx CEO.